You are here

Article Text

Article menu
Download PDFPDF
News and notes
News and updates from palliativedrugs.com
  1. Andrew Wilcock1 and
  2. Sarah Charlesworth2
  1. 1Department of Palliative Medicine, University of Nottingham, Nottingham, UK
  2. 2palliativedrugs.com, Hayward House Study Centre, Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, UK
  1. Correspondence to Sarah Charlesworth, palliativedrugs.com, Hayward House Study Centre, Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, UK; s.charlesworth{at}nhs.net

https://doi.org/10.1136/bmjspcare-2015-001036

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The website http://www.palliativedrugs.com has provided essential independent information about drugs used in palliative and hospice care for over a decade, and has over 30 000 members from 169 Countries. It contains the on-line Palliative Care Formulary (PCF) and provides free access to a Bulletin board to stimulate questions and share experiences, a Document library containing 475 items of useful information and a Syringe Driver Survey Database containing details of over 2350 different drug combinations. Territory-specific book versions (the UK Palliative Care Formulary 5th edition, Hospice and Palliative Care Formulary USA 2nd edition and Palliative Care Formulary Canadian edition) a PDF version of the PCF and subscription to the continually updated on-line PCF can also be purchased via the website. This feature provides a selection of items that have featured in the News and Latest additions sections in recent months; for additional information, please register for free on the website.

    Safety updates

    Further measures to minimise risk of osteonecrosis of the jaw with denosumab and intravenous bisphosphonates

    Following a review by UK Medicines and Healthcare products Regulatory Agency and other European regulators, denosumab 120 mg is now contraindicated in patients with unhealed lesions from dental or oral surgery.

    New patient reminder cards are also to be given to those receiving denosumab or intravenous bisphosphonates informing them of the risk of osteonecrosis of the jaw and precautions to take before and during treatment.

    Hot topics

    Guideline consultations

    UK National Institute for Health and Care Excellence has recently published draft guideline consultations for:

    • The care of the dying adult (closed 9 September 2015). This includes anticipatory prescribing, assisted hydration and the pharmacological management of pain, breathlessness, …

    View Full Text

    Footnotes

    • Twitter Follow palliativedrugs.com at @palliativedrugs

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.